Anixa Biosciences Unveils Promising Vaccine Data
In a noteworthy development for cancer treatment, Anixa Biosciences, Inc. is set to present the final results of its Phase 1 clinical trial for a groundbreaking breast cancer vaccine. The presentation will take place at the upcoming San Antonio Breast Cancer Symposium (SABCS), marking a significant milestone for the company and the field of oncology.
Significance of the Phase 1 Trial
The Phase 1 trial focused on evaluating the safety and immunogenicity of an innovative vaccine based on alpha-lactalbumin (aLA), which targets breast cancer. Backed by funding from the U.S. Department of Defense, this clinical trial has generated data that may transform how breast cancer is treated and prevented in the future. Dr. Justin Johnson, who played a pivotal role as the Program Manager at Cleveland Clinic, will be delivering the presentation titled "Final Results of a Phase I Trial of alpha-lactalbumin (aLA) Vaccine for Breast Cancer".
Details of the Upcoming Presentation
Attendees at SABCS can expect a comprehensive overview of the studies conducted, as the presentation will delve into the most detailed data gathered to date regarding the vaccine's effectiveness. The findings will also be submitted to the FDA, guiding the next steps in the planning and development of Phase 2 trials.
Presentation Highlights
Here are essential details for the upcoming presentation:
- Abstract Number: 765
- Presentation Number: PS4-06-19
- Presentation Title: Final Results of a Phase I Trial of an Alpha-lactalbumin (aLA) Vaccine for Breast Cancer
- Date and Time: Thursday, December 11, 2025, 5:00–6:30 PM CST
Statements from Leadership
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed optimism regarding the trial outcomes. "The data from this human clinical trial are encouraging and have exceeded our expectations," he stated. Highlighting the foundational work of Dr. Vincent Tuohy, a pioneering figure whose research built the technology behind this vaccine, Dr. Kumar emphasized the vaccine's potential to redefine breast cancer prevention and treatment.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology firm dedicated to innovative cancer therapeutics. The company is advancing its therapeutic portfolio which includes a collaborative ovarian cancer immunotherapy program with Moffitt Cancer Center. This collaborative effort utilizes an inventive CAR-T cell therapy approach, displaying Anixa’s commitment to exploring and developing next-generation cancer treatments.
Additionally, Anixa is working on various cancer vaccines aimed at tackling difficult-to-treat malignancies, further showcasing its dedication to addressing high-incidence cancers such as lung, colon, and prostate cancers. These vaccine initiatives pivot on the concept of immunizing patients against proteins that appear in specific cancer forms, which are termed "retired" proteins.
The exclusive license agreement with Cleveland Clinic for both the breast and ovarian cancer vaccines underscores Anixa's strategy of partnering with renowned research institutions to foster advancements in the field.
Frequently Asked Questions
What is the focus of Anixa Biosciences?
Anixa Biosciences is dedicated to the development of innovative treatments for cancer, including vaccines and therapies targeting breast and ovarian cancer.
Where will the Phase 1 results be presented?
The results will be presented at the San Antonio Breast Cancer Symposium (SABCS).
Who is delivering the presentation at SABCS?
Dr. Justin Johnson, a Program Manager at Cleveland Clinic, will deliver the presentation on the vaccine results.
How is the vaccine funded?
The development of the vaccine has been supported by funding from the U.S. Department of Defense.
What is the significance of this vaccine trial?
The trial represents a key step towards potentially transforming breast cancer treatment and prevention, providing vital data to inform future developments.
